Welcome to our dedicated page for Opthea SEC filings (Ticker: CKDXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Opthea Limited filings document foreign-issuer reporting for a registrant with executive offices in Australia that files on Form 20-F and furnishes current reports on Form 6-K. The filings include press-release exhibits covering annual meeting results, quarterly report and cashflow materials, and other company announcements incorporated by reference into its Form S-8 registration statement.
The filing record also includes Form 25 notifications for the voluntary withdrawal of Opthea's American Depositary Shares from listing and registration on The Nasdaq Global Select Market. Those notices describe the ADS class as representing eight ordinary shares and include related exchange-listing and governance disclosures.
Opthea Limited filed a Form 25 to remove its American Depositary Shares from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The securities are ADSs, each representing eight ordinary shares, previously listed on The Nasdaq Global Select Market. The notification was signed by Chief Executive Officer Jeremy Levin on November 10, 2025.
Opthea Limited filed a Form 25 to remove its American Depositary Shares from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The securities are ADSs, each representing eight ordinary shares, previously listed on The Nasdaq Global Select Market. The notification was signed by Chief Executive Officer Jeremy Levin on November 10, 2025.
Opthea Limited filed a Form 6-K noting it issued a press release announcing its intention to voluntarily delist its American Depositary Shares from the Nasdaq Global Select Market.
The press release, dated October 29, 2025, is furnished as Exhibit 99.1 and is incorporated by reference into Opthea’s Form S-8 (File No. 333-251052). This notice focuses on the planned delisting of Opthea’s ADSs from Nasdaq as described in the press release.
Opthea Limited filed a Form 6-K noting it issued a press release announcing its intention to voluntarily delist its American Depositary Shares from the Nasdaq Global Select Market.
The press release, dated October 29, 2025, is furnished as Exhibit 99.1 and is incorporated by reference into Opthea’s Form S-8 (File No. 333-251052). This notice focuses on the planned delisting of Opthea’s ADSs from Nasdaq as described in the press release.
Opthea Limited submitted a Form 6-K as a foreign private issuer, primarily to furnish a press release announcing the appointment of a new company secretary. The report lists this press release as Exhibit 99.1 and is signed on behalf of Opthea by Executive Officer Jeremy Levin.
Opthea Limited submitted a Form 6-K as a foreign private issuer, primarily to furnish a press release announcing the appointment of a new company secretary. The report lists this press release as Exhibit 99.1 and is signed on behalf of Opthea by Executive Officer Jeremy Levin.
Opthea Limited, a foreign private issuer, filed a Form 6-K for October 2025. The filing mainly furnishes a press release, listed as Exhibit 99.1, announcing that Opthea received an A$10.8 million R&D Tax Incentive, a government-related research and development benefit.
Opthea Limited (CKDXF) filed its Form 20-F describing a company without product revenues that continues development of biologic candidates including sozinibercept and OPT-302. Management disclosed that it has not obtained regulatory approval for any product candidate, has incurred significant losses, and expects to need additional capital to complete clinical development. The company may reformulate candidates to target VEGF-C/D; if reformulation is not viable directors may consider a return of capital and ceasing operations.
The report discloses a resolution of the Development Funding Agreement: DFA investors provided US$20.0 million and were issued equity equal to 9.99% fully diluted (136,661,003 ordinary shares), liens were released and the DFA terminated. As of August 30, 2025 the Group had US$19.3 million of cash and cash equivalents. Management concluded internal control over financial reporting was not effective as of June 30, 2025 due to errors in accounting for the Funding Agreement and investor options.
Opthea Limited has filed a Form 6-K as a foreign private issuer for September 2025. The filing mainly serves as a cover to provide two key documents to investors and regulators.
Exhibit 99.1 is titled “Opthea Limited Annual Report 2025,” and Exhibit 99.2 is titled “Opthea Corporate Governance Statement 2025,” indicating the company has submitted its latest annual reporting and governance information.